Message from the President
Created date：February 15th, 2018
I would like to express my aspiration for the future of JSPHO on my inauguration of as the president.
Four years passed after merging the Japanese Society of Pediatric Hematology (JSPH) and the Japanese Society of Pediatric Cancer (JSPC). The first president, Dr. Eiichi Ishi and the second president, Dr. Keizo Horibe, made great efforts to establish a base of JSPHO. The new secretary office was set up, and the organization was shifted to a general incorporated association. I would like to promote activities of the society more in cooperation with executive board members and other JSPHO members.
The mission of this society is to contribute to the advancement ofin pediatric hematology and oncology and to support children, adolescents, and their families who are fighting against blood diseases and cancers. To achieve the missions, the society operates an accreditation program for the specialists and provides information on hospitals which that offer highly qualityfied care for children with blood diseases and cancers. In addition, the society provides learning opportunities to all professions participating in clinical practices in pediatric hematology and oncology.
The case registration project formerly operated by JSPH and other societies should be reformed into a new type of epidemiological study including outcome surveys along a new law.
Furthermore, JSPHO must collaborate with Japan Children’s Cancer Group (JCCG), a recently established national study group for childhood cancer and other academic societies to solve various problems of our patients.
With the efforts of JSPC, pediatric cancer was listed out in Cancer Control Act by the Japanese Government. Then, the enhancement of medical systems for pediatric cancer has been conducted mainly in two national centers (National Cancer Center and National Center for Child Health and Development) and 15 core hospitals for pediatric cancer. JSPHO will make efforts to accelerate the movements. We should cooperate with the specialists of adult cancer because enhancements of the approach to cancer in adolescents and young adults and transition of childhood cancer survivors are the emerging issues in oncology.
Case registration project was transferred from JSPH to JSPHO in cooperation with other existing systems to produce high-quality data. It should be reformed and expanded to include solid tumors.
We will approach various issues of childhood cancer such as refractory diseases, late effects, and secondary cancers among childhood cancer survivors and nuclear exposure of children in Fukushima. We will make contributions to solve these problems by collaborating with scientists and other academic associations.
We have to make our activities more globalized. We will advance collaborations with foreign and international associations to improve clinical outcomes of pediatric blood diseases and cancers. We already introduced English sessions at the JSPHO annual meeting and appointed Pediatric Blood & Cancer as our official journal. We will enhance our partnership with Asian countries as well as western countries.
Better total care for children with cancer may depend on collaboration with patients, family members, and supporters. We continue the efforts to communicate with patients and their families.
I will do my best to manage JSPHO activities properly and to achieve these goals with JSPHO members.
I would appreciate your understanding and support.
The Japanese Society of Pediatric Hematology and Oncology